DelveInsight’s “Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Psoriatic Arthritis, historical and forecasted epidemiology, as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover Key Insights into the Psoriatic Arthritis Market with DelveInsight’s In-Depth Report @ Psoriatic Arthritis Market Size
Key Takeaways from the Psoriatic Arthritis Market Report
- In May 2025, Teva Pharmaceuticals and Alvotech announced that the FDA has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). Starting April 30, 2025, SELARSDI is available in all presentations matching the reference product, for the treatment of adults and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.
- In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following FDA approval in December 2024. STEQEYMA is approved for the same indications as STELARA, offering consistent treatment for patients and healthcare providers.
- According to DelveInsight’s analysis, in 2023, Psoriatic Arthritis was observed to affect females more frequently than males, with females accounting for approximately 15% more PsA cases compared to males.
- The National Psoriatic Foundation reports that approximately 1 in 3 individuals, or 30%, with psoriasis develop Psoriatic Arthritis, affecting up to 2.4 million Americans.
- In 2023, the majority of Psoriatic Arthritis cases were of moderate severity, comprising approximately 60% of cases, followed by severe and mild forms.
- In the US in 2023, the age group 50–59 years had the highest prevalence of Psoriatic Arthritis, while the 18–29 age group had the lowest number of cases.
- The leading Psoriatic Arthritis companies such as UCB Biopharma, Sun Pharmaceutical Industries Limited, Bristol Myers Squibb, Affibody AB, and others.
- Promising Psoriatic Arthritis Therapies such as bimekizumab, tildrakizumab, deucravacitinib, izokibep, and others.
Stay ahead in the Psoriatic Arthritis Therapeutics Market with DelveInsight’s Strategic Report @ Psoriatic Arthritis Market Outlook
Psoriatic Arthritis Epidemiology Segmentation in the 7MM
- Total Prevalent Cases of Psoriatic Arthritis
- Total Diagnosed Cases of Psoriatic Arthritis
- Gender-specific Cases of Psoriatic Arthritis
- Age-specific Cases of Psoriatic Arthritis
- Severity-specific Cases of Psoriatic Arthritis
Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ Psoriatic Arthritis Prevalence
Psoriatic Arthritis Pipeline Analysis
• Bimekizumab: UCB Biopharma
Bimekizumab is an investigational, humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A. The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical program. The company is evaluating the drug in multiple Phase III Psoriatic Arthritis clinical studies for PsA.
• Tildrakizumab (ILUMYA): Sun Pharmaceutical Industries Limited
Tildrakizumab is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the US. The drug is currently being evaluated in Phase III Psoriatic Arthritis clinical trials in subjects with active Psoriatic Arthritis with prior exposure to an anti-TNF agent(s) as well as in anti-TNF naïve subjects with active Psoriatic Arthritis.
• Deucravacitinib (SOTYKTU): Bristol Myers Squibb
Deucravacitinib is a promising therapy currently in late-stage clinical development for Psoriatic Arthritis. This novel treatment represents an important advancement in the therapeutic landscape for PsA patients.
• Izokibep: Affibody AB
Izokibep is another emerging therapy in late-stage development, offering potential new treatment options for patients with Psoriatic Arthritis.
Psoriatic Arthritis Drugs Market Insights
The current Psoriatic Arthritis treatment market landscape includes medications such as HUMIRA (adalimumab), OTEZLA (apremilast), COSENTYX (secukinumab), CIMZIA (certolizumab pegol), and BIMZELX (bimekizumab), among others. For PsA patients who do not respond to TNFi monotherapy, IL-17 inhibitors are typically favored over IL-12/23 inhibitors, abatacept, or tofacitinib. However, IL-12/23 inhibitors serve as an alternative for patients with coexisting IBD or those seeking less frequent dosing than IL-17 inhibitors.
Although many effective PsA therapies, including csDMARDS, TNF inhibitors, various anti-IL inhibitors, and a variety of small molecule therapeutics, have been introduced over the last decade, many patients often do not respond to treatment due to various resistance symptoms. Concerns over long-term safety profiles of csDMARDS and currently available biologics may limit their use, and patients can find treatments difficult due to regular blood monitoring, concerns of side effects, method of administration, and the impact on metabolic risk.
Get In-Depth Knowledge on Psoriatic Arthritis Market Trends and Forecasts with DelveInsight @ Psoriatic Arthritis Treatment Market
Psoriatic Arthritis Companies
UCB Biopharma, Sun Pharmaceutical Industries Limited, Bristol Myers Squibb, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, and others.
Psoriatic Arthritis Market Outlook
Psoriatic Arthritis is a form of arthritis associated with psoriasis, a chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. In most Psoriatic Arthritis patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.
No cure for Psoriatic Arthritis exists, so treatment goals are to slow disease progression, improve quality of life, lessen pain, and preserve range of motion. In the 7MM, the Psoriatic Arthritis market size was approximately USD 9 billion in 2021 and is expected to change significantly during the study period 2020–2034.
Scope of the Psoriatic Arthritis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Forecast Period- 2024-2034
- Psoriatic Arthritis Companies- UCB Biopharma, Sun Pharmaceutical Industries Limited, Bristol Myers Squibb, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, and others
- Psoriatic Arthritis Therapies- Bimekizumab, Tildrakizumab, Deucravacitinib, Izokibep, and others
- Psoriatic Arthritis Market Access & Reimbursements, Unmet Needs and Perspectives
- Psoriatic Arthritis SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive Psoriatic Arthritis Market Report @ Psoriatic Arthritis Market Drivers and Barriers
Table of Contents
- Key Insights
- Report Introduction
- Psoriatic Arthritis Market Overview at a Glance
- Executive Summary of Psoriatic Arthritis
- Disease Background and Overview
- Epidemiology and Patient Population
- Patient Journey of Psoriatic Arthritis
- Psoriatic Arthritis Marketed Products
- Psoriatic Arthritis Emerging Therapies
- Other Assets
- Psoriatic Arthritis (PsA): Seven Major Market Analysis
- SWOT Analysis
- KOL Views
- Psoriatic Arthritis Unmet Needs
- Psoriatic Arthritis Market Access
- Acronyms and Abbreviations
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
